Stockreport

ALEC Stock Tanks as Alzheimer's Drug Fails in Mid-Stage Study [Yahoo! Finance]

Alector, Inc.  (ALEC) 
Last alector, inc. earnings: 3/24 04:05 pm Check Earnings Report
PDF The phase II INVOKE-2 study evaluated the safety and efficacy of AL002 in slowing disease progression in individuals with early AD. The study's primary endpoint was to [Read more]